Literature DB >> 23607270

C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.

A Landsem1, E W Nielsen, H Fure, D Christiansen, J K Ludviksen, J D Lambris, B Østerud, T E Mollnes, O-L Brekke.   

Abstract

Both the complement system and tissue factor (TF), a key initiating component of coagulation, are activated in sepsis, and cross-talk occurs between the complement and coagulation systems. C1-inhibitor (C1-INH) can act as a regulator in both systems. Our aim in this study was to examine this cross-talk by investigating the effects of C1-INH on Escherichia coli-induced haemostasis and inflammation. Fresh human whole blood collected in lepirudin was incubated with E. coli or ultrapurified E. coli lipopolysaccharide (LPS) in the absence or presence of C1-INH or protease-inactivated C1-INH. C3 activation was blocked by compstatin, a specific C3 convertase inhibitor. TF mRNA was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and TF surface expression was measured by flow cytometry. In plasma, the terminal complement complex, prothrombin F1·2 (PTF1·2) and long pentraxin 3 (PTX3) were measured by enzyme-linked immunosorbent assay (ELISA). Cytokines were analysed using a multiplex kit. C1-INH (1·25-5 mg/ml) reduced both LPS- and E. coli-induced coagulation, measured as a reduction of PTF1·2 in plasma, efficiently and dose-dependently (P < 0·05). Both LPS and E. coli induced marked up-regulation of TF mRNA levels and surface expression on whole blood monocytes. This up-regulation was reduced efficiently by treatment with C1-INH (P < 0·05). C1-INH reduced the release of PTX3 (P < 0·05) and virtually all cytokines measured (P < 0·05). Complement activation was inhibited more efficiently with compstatin than with C1-INH. C1-INH inhibited most of the other readouts more efficiently, consistent with additional non-complement-dependent effects. These results indicate that complement plays a role in activating coagulation during sepsis and that C1-INH is a broad-spectrum attenuator of the inflammatory and haemostatic responses.
© 2013 British Society for Immunology.

Entities:  

Keywords:  C1-inhibitor; coagulation; complement; tissue factor; whole blood

Mesh:

Substances:

Year:  2013        PMID: 23607270      PMCID: PMC3722922          DOI: 10.1111/cei.12098

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.

Authors:  P M Jansen; B Eisele; I W de Jong; A Chang; U Delvos; F B Taylor; C E Hack
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

2.  A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

Review 3.  Contact system activation in severe infectious diseases.

Authors:  Sonja Oehmcke; Heiko Herwald
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

4.  Sepsis in European intensive care units: results of the SOAP study.

Authors:  Jean-Louis Vincent; Yasser Sakr; Charles L Sprung; V Marco Ranieri; Konrad Reinhart; Herwig Gerlach; Rui Moreno; Jean Carlet; Jean-Roger Le Gall; Didier Payen
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

5.  Generation of C5a in the absence of C3: a new complement activation pathway.

Authors:  Markus Huber-Lang; J Vidya Sarma; Firas S Zetoune; Daniel Rittirsch; Thomas A Neff; Stephanie R McGuire; John D Lambris; Roscoe L Warner; Michael A Flierl; Laszlo M Hoesel; Florian Gebhard; John G Younger; Scott M Drouin; Rick A Wetsel; Peter A Ward
Journal:  Nat Med       Date:  2006-05-21       Impact factor: 53.440

6.  A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes.

Authors:  C S Engstad; K Lia; O Rekdal; J O Olsen; B Osterud
Journal:  J Leukoc Biol       Date:  1995-11       Impact factor: 4.962

7.  The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation.

Authors:  Emanuela Napoleone; Angelomaria di Santo; Giuseppe Peri; Alberto Mantovani; Giovanni de Gaetano; Maria Benedetta Donati; Roberto Lorenzet
Journal:  J Leukoc Biol       Date:  2004-07       Impact factor: 4.962

8.  Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component.

Authors:  F Breviario; E M d'Aniello; J Golay; G Peri; B Bottazzi; A Bairoch; S Saccone; R Marzella; V Predazzi; M Rocchi
Journal:  J Biol Chem       Date:  1992-11-05       Impact factor: 5.157

9.  Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.

Authors:  C de Zwaan; A H Kleine; J H C Diris; J F C Glatz; H J J Wellens; P F W Strengers; M Tissing; C E Hack; M P van Dieijen-Visser; W T Hermens
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

10.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more
  7 in total

1.  Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Authors:  Caroline Gravastrand; Shamal Hamad; Hilde Fure; Bjørg Steinkjer; Liv Ryan; Josè Oberholzer; John D Lambris; Igor Lacík; Tom Eirik Mollnes; Terje Espevik; Ole-Lars Brekke; Anne Mari Rokstad
Journal:  Acta Biomater       Date:  2017-05-30       Impact factor: 8.947

Review 2.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

3.  Experimental hypercoagulable state induced by tissue factor expression in monocyte-derived dendritic cells and its modulation by C1 inhibitor.

Authors:  Shogo Kasuda; Yoshihiko Sakurai; Kohei Tatsumi; Tomohiro Takeda; Risa Kudo; Katsuya Yuui; Katsuhiko Hatake
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

4.  Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Janette Bester; Christopher J Robinson; Douglas B Kell
Journal:  J R Soc Interface       Date:  2016-09       Impact factor: 4.118

Review 5.  New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

6.  Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.

Authors:  Alexander Röth; Wilma Barcellini; Tor Henrik Anderson Tvedt; Yoshitaka Miyakawa; David J Kuter; Jun Su; Xiaoyu Jiang; William Hobbs; Jaime Morales Arias; Frank Shafer; Ilene C Weitz
Journal:  Ann Hematol       Date:  2022-08-23       Impact factor: 4.030

Review 7.  Roles of Immune Cells in Hereditary Angioedema.

Authors:  Anne Lise Ferrara; Leonardo Cristinziano; Angelica Petraroli; Maria Bova; Maria Celeste Gigliotti; Simone Marcella; Luca Modestino; Gilda Varricchi; Mariantonia Braile; Maria Rosaria Galdiero; Giuseppe Spadaro; Stefania Loffredo
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-29       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.